The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions
Open accessAbstract
Psoriasis is a chronic inflammatory skin disease in which epidermal hyperplasia results from skin infiltration by type I T lymphocytes and release of associated cytokines. A multifunctional cytokine, rhIL-11, modulates macrophage and type I T-lymphocyte function in cell culture and shows anti-inflammatory activity in animal models. We are testing subcutaneous delivery of rhIL-11 to patients with psoriasis in a phase 1 open-label dose-escalation clinical trial. Tissue was obtained from lesional and uninvolved skin before and during treatment with rhIL-11 and was examined by histology/immunohistochemistry and quantitative RT-PCR. Expression of over 35 genes was examined in all patients, and multiple genetic markers of psoriasis were identified. Expression of numerous proinflammatory genes was elevated in psoriatic tissue compared with nonlesional skin. Seven of 12 patients responded well to rhIL-11 treatment. Amelioration of disease by rhIL-11, as shown by reduced keratinocyte proliferation and cutaneous inflammation, was associated with decreased expression of products of disease-related genes, including K16, iNOS, IFN-gamma, IL-8, IL-12, TNF-alpha, IL-1beta, and CD8, and with increased expression of endogenous IL-11. We believe that this is the first study in humans to indicate that type I cytokines can be selectively suppressed by an exogenous immune-modifying therapy. The study highlights the utility of pharmacogenomic monitoring to track patient responsiveness and to elucidate anti-inflammatory mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Cited by
Lee, E., Trepicchio, W. L., Oestreicher, J. L., Pittman, D., Wang, F., Chamian, F., Dhodapkar, M., & Krueger, J. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030451 · Cited by 899
Self-citationImmune surveillance in the skin: mechanisms and clinical consequences
Kupper, T. S., & Fuhlbrigge, R. C. (2004) · Nature Reviews Immunology · doi:10.1038/nri1310 · Cited by 805
Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
The cytokine network involved in the host immune response to periodontitis
Pan, W., Wang, Q., & Chen, Q. (2019) · International Journal of Oral Science · doi:10.1038/s41368-019-0064-z · Cited by 696
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Self-citationRecent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Nickoloff, B. J., & Nestle, F. O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422147 · Cited by 544
“While anti-inflammatory effects of IL-10 and IL-11 were relatively modest compared with those of the TNF-α inhibitors, clearly the entire field is rapidly moving from nonspecific treatments such as arsenic, corticosteroids, methotrexate, and UV light to more selective treatments aimed at defined pathogenic targets for…”
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
Ghoreschi, K., Thomas, P., Breit, S., Dugas, M., Mailhammer, R., van Eden, W., van der Zee, R., Biedermann, T., Prinz, J., Mack, M., et al. (2003) · Nature Medicine · doi:10.1038/nm804 · Cited by 453
Gröne, A. (2002) · Veterinary Immunology and Immunopathology · doi:10.1016/s0165-2427(02)00136-8 · Cited by 384
The Immunology of Psoriasis-Current Concepts in Pathogenesis
Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08991-7 · Cited by 346
Zhou, X., Krueger, J. G., Kao, M.-C. J., Lee, E., Du, F., Menter, A., Wong, W. H., & Bowcock, A. M. (2003) · Physiological Genomics · doi:10.1152/physiolgenomics.00157.2002 · Cited by 295
Self-citationLew, W., Bowcock, A. M., & Krueger, J. G. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.006 · Cited by 284
Self-citationWang, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27180 · Cited by 276
“…of directly targeting TNF-a in the treat-ment of human psoriasis (6, 9), therapies that most likely impair macrophage function by diminishing the production and release of TNF-a , such as IL-4 (50), IL-11 (51), and anti–IL-12 (52), have previously been reported to improve this medical condition.”
Host response modulation in the management of periodontal diseases
Salvi, G. E., & Lang, N. P. (2005) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2005.00785.x · Cited by 276
Oxidative stress in the pathogenesis of psoriasis
Zhou, Q., Mrowietz, U., & Rostami-Yazdi, M. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.06.033 · Cited by 274
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
Brück, J., Dringen, R., Amasuno, A., Pau‐Charles, I., & Ghoreschi, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13548 · Cited by 128
Walters, I. B., Ozawa, M., Cardinale, I., Gilleaudeau, P., Trepicchio, W. L., Bliss, J., & Krueger, J. G. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.2.155 · Cited by 83
“Recent measures of ongoing cytokine synthesis in psoriatic lesions by reverse transcription–polymerase chain reaction (RT-PCR) techniques confirm the predominance of proinflammatory cytokine messenger RNAs (mRNAs) (IFN- , TNF- , and IL-8) and a paucity of suppressive cytokine mRNAs (IL-4 and IL-10).(4) In addition, IL…”
BackgroundMethodResultInfluentialSelf-citation
Metadata
- Authors
- Trepicchio, W. L., Ozawa, M., Walters, I. B., Kikuchi, T., Gilleaudeau, P., Bliss, J. L., Schwertschlag, U., Dorner, A. J., & Krueger, J. G.
- Venue
- Journal of Clinical Investigation
- Published
- 1999-12-01
- Volume
- 104
- Issue
- 11
- Pages
- 1527-1537
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1976494868
- Cited by
- 217
- References
- 1
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.